Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy.
Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, Hew L, Nolte L, Körtvelyessy P, Göpfert JC, Ruprecht K, Somps CJ, Blohmer JU, Sehouli J, Endres M, Boehmerle W. Huehnchen P, et al. Among authors: bangemann n. JCI Insight. 2022 Mar 22;7(6):e154395. doi: 10.1172/jci.insight.154395. JCI Insight. 2022. PMID: 35133982 Free PMC article.
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial.
Huehnchen P, Bangemann N, Lischewski S, Märschenz S, Paul F, Schmitz-Hübsch T, Blohmer JU, Eberhardt C, Rauch G, Flöel A, Adam S, Schwenkenbecher P, Meinhold-Heerlein I, Hoffmann O, Ziemssen T, Endres M, Boehmerle W. Huehnchen P, et al. Among authors: bangemann n. Front Med (Lausanne). 2022 Aug 11;9:967964. doi: 10.3389/fmed.2022.967964. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36035422 Free PMC article.
Feasibility and Possible Effects of Mindful Walking and Moderate Walking in Breast Cancer Survivors: A Randomized Controlled Pilot Study With a Nested Qualitative Study Part.
Schröder ML, Stöckigt B, Binting S, Tissen-Diabaté T, Bangemann N, Goerling U, Kröz M, Blohmer JU, Ortiz M, Brinkhaus B. Schröder ML, et al. Among authors: bangemann n. Integr Cancer Ther. 2022 Jan-Dec;21:15347354211066067. doi: 10.1177/15347354211066067. Integr Cancer Ther. 2022. PMID: 35045736 Free PMC article. Clinical Trial.
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.
Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C. Müller BM, et al. Among authors: bangemann n. PLoS One. 2013 Jun 27;8(6):e68252. doi: 10.1371/journal.pone.0068252. Print 2013. PLoS One. 2013. PMID: 23826382 Free PMC article.
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling.
Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C. Brockmöller SF, et al. Among authors: bangemann n. J Proteome Res. 2012 Feb 3;11(2):850-60. doi: 10.1021/pr200685r. Epub 2011 Dec 15. J Proteome Res. 2012. PMID: 22070544
Correction to "Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer─Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling".
Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C. Brockmöller SF, et al. Among authors: bangemann n. J Proteome Res. 2022 Jul 1;21(7):1787. doi: 10.1021/acs.jproteome.2c00181. Epub 2022 Jun 1. J Proteome Res. 2022. PMID: 35642679 No abstract available.
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Schaller G, et al. Among authors: bangemann n. J Clin Oncol. 2007 Aug 1;25(22):3246-50. doi: 10.1200/JCO.2006.09.6826. Epub 2007 Jun 18. J Clin Oncol. 2007. PMID: 17577021 Clinical Trial.
17 results